The US Food and Drug Administration (FDA) on Tuesday approved Kisunla (donanemab-azbt) injection, produced by Eli Lilly, for the treatment of Alzheimers disease. Kisunla is the third amyloid-targeting drug approved by the FDA since 2021, following two treatments Aduhelm and Leqembi. Kisunla slowed the cognitive and functional decline in patients with mild cognitive impairment by 35 percent over 18 months. The drug removes beta-amyloid that accumulates in the brains of patients with Alzheimer's disease. The estimated cost for a six-month course of the therapy is $12,522. A full year of treatment is protected to cost $32,000, according to Eli Lilly. Source: Qatar News Agency
Related Posts
Israeli officer and soldier seriously injured in Gaza and Lebanon
The Israeli army announced on Saturday evening that an officer and a soldier were seriously injured during the battles in Gaza and Lebanon during Yom Kippur.
The army said that an officer from the military engineering school was seriously wounded ear…
Shenzhou-18 Spaceship Successfully Docks with Chinese Space Station
A spaceship carrying three astronauts from China’s Shenzhou-18 mission safely docked at Tiangong space station Friday, said China Manned Space Agency.
By early Friday the spacecraft had “successfully docked” with the space station, the Chinese news …
UN Secretary General arrives in the kingdom to participate in Bahrain Summit
Manama, His Excellency Mr. António Guterres, the Secretary General of the United Nations (UN), today arrived in the Kingdom of Bahrain to attend in the 33rd Arab Summit.
Upon arrival, the Secretary General was received by Shaikh Khalid bin Ahmed bin …